Supercharged immune cells take on tough pancreatic cancer
NCT ID NCT06828328
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of chemotherapy. The main goal is to check safety, but researchers will also watch for tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gene-edited tumor infiltrating lymphocytes (GC203 TIL)
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer that has not responded to standard therapies.
What could go wrong
This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The treatment involves strong chemotherapy beforehand and may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••